Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EBS, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Raxibacumab FDA approved Dec 2012 · Raxibacumab |
Infections, Bacterial | Phase 4 · NCT02339155 | Completed |
| Brincidofovir FDA approved Jun 2021 · Tembexa |
Smallpox | Phase 1 · NCT05935917 | Completed |
| Anti-Vector Antibody | Infections, Bacterial | Phase 4 · NCT02339155 | Completed |
| Vaccination with ACAM2000 | Smallpox Vaccine Adverse Reaction | Phase 4 · NCT02443623 | Completed |
| Sample Collection | Infections, Bacterial | Phase 4 · NCT02177721 | Not yet recruiting |
| Hepatitis B Vaccine | Healthy Volunteers | Phase 3 · NCT01311674 | Terminated |
| BioThrax | Anthrax | Phase 3 · NCT03877926 | Completed |
| AV7909 | Anthrax | Phase 3 · NCT03877926 | Completed |
| Zanolimumab | T Cell Lymphoma | Phase 2/3 · NCT00877656 | Completed |
| ACAM2000 | Smallpox Vaccine Adverse Reaction | Phase 3 · NCT01158157 | Completed |
| DNA Damage-Inducible Transcript 3 Protein | T-cell Lymphoma | Phase 2 · NCT00893516 | Terminated |
| Dose of 1.1 x 10^10 CFU (Cohort 3) | Typhoid | Phase 2 · NCT00679172 | Completed |
| Dose of 5.0 x 10^9 CFU (Cohort 1) | Typhoid | Phase 2 · NCT00679172 | Completed |
| ACAM2000 Smallpox Vaccine | Smallpox | Phase 2 · NCT00053482 | Completed |
| Dose of 7.5 x 10^9 CFU (Cohort 2) | Typhoid | Phase 2 · NCT00679172 | Completed |
| Dose of of 1.7 x 10^10 CFU (Cohort 4) | Typhoid | Phase 2 · NCT00679172 | Completed |
Also used in these trials (approved or third-party drugs, not EBS's own candidates): Diphenhydramine Hydrochloride, Adjuvant, Ciprofloxacin, Doxycycline.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EBS holds $175.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EBS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 4,651,339 | 9.05% | 2026-06-30 |
| Oak Hill Advisors LP | Institution (13G, 5%+) | 4,014,015 | 7.81% | 2026-09-30 |
| American Century Investment Management, | Institution (13G, 5%+) | 3,312,329 | 6.44% | 2026-09-30 |
| Dimensional Fund Advisors LP | Institution (13G, 5%+) | 2,757,158 | 5.36% | 2026-03-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 2,696,375 | 5.24% | 2025-12-31 |
| Joseph C Papa President and CEO, Director · +1.78M options |
Insider | 493,153 | 0.96% | 2026-04-29 |
| Richard S Lindahl EVP, Chief Financial Officer · +557,346 options |
Insider | 374,083 | 0.73% | 2026-06-08 |
| Coleen Glessner EVP, Quality & Ethics, and CPL · +294,447 options |
Insider | 202,201 | 0.39% | 2026-06-08 |
| Stephanie Duatschek EVP, CGO |
Insider | 197,416 | 0.38% | 2026-08-05 |
| William Hartzel SVP, Bioservices · +259,545 options |
Insider | 185,558 | 0.36% | 2026-06-08 |
| Simon C Lowry SVP, R&D, CMO · +147,833 options |
Insider | 177,914 | 0.35% | 2026-04-29 |
| Jessica Perl SVP, General Counsel, Corp Sec · +142,647 options |
Insider | 165,286 | 0.32% | 2026-04-29 |
Share count 51,415,182 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EBS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →